ASCORBYL GAMOLENATE | 109791-32-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ASCORBYL GAMOLENATE
• 英文别名: ascorbic acid 6-[(z,z,z)-octadeca-6,9,12-trienoate]；[(2S)-2-[(2R)-3,4-dihydroxy-5-oxo-2H-furan-2-yl]-2-hydroxyethyl] (6Z,9Z,12Z)-octadeca-6,9,12-trienoate
• CAS: 109791-32-4
• 化学式: C₂₄H₃₆O₇
• 分子量: 436.546
• InChiKey: FLRQOWAOMJMSTP-JJTRIOAGSA-N

物化性质

• 沸点：
  562.2±50.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N,N-二甲基乙酰胺 、 γ-linolenic acid 、 维生素 C 在 盐酸 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 以88%的产率得到ASCORBYL GAMOLENATE
  参考文献：
  名称：

  N-alkylpolyhydroxyamine salts of polyunsaturated fatty acids

  摘要：

  一种N-烷基多羟胺盐，其为n-6或n-3必需脂肪酸（EFA）的6-脱饱和步骤之外的产物，或者为具有16至26个碳原子和最多六个双键的任何多不饱和脂肪酸的盐，这些双键以顺式或反式构型存在，该盐是通过脂肪酸本身或以共价衍生物的形式与脂肪酸形成的，通过具有自由酸功能的双功能化合物的羧基。

  公开号：

  US05990164A1

文献信息

• [EN] SKIN CARE PRODUCTS, AS WELL AS FOODS AND BEVERAGES CONTAINING 6-O-PUFA ASCORBIC ESTERS<br/>[FR] PRODUITS POUR LES SOINS DE LA PEAU, ET ALIMENTS ET BOISSONS CONTENANT DES ESTERS 6-O-PUFA ASCORBIQUES
  申请人：SUNTORY LTD

  公开号：WO2006019186A1

  公开（公告）日：2006-02-23

  Skin care products which contain as a vitamin C component 6-O-PUFA ascorbates represented by general formula (I): RCO-A (I)where RCO- is an acyl group derived from a polyunsaturated fatty acid, and A is a residue of ascorbic acid that binds by -O- derived from the hydroxyl group in ascorbic acid. The products show improved transfer of ascorbic acid to tissues or cells, allow the functions of ascorbic acid to be exhibited efficiently, and also have the potential to show the functions of PUFAs. Also provided are foods and beverages that contain 6-O-PUFA ascorbates represented by general formula (I).

  含有维生素C成分6-O-PUFA抗坏血酸酯的护肤产品，其一般化学式表示为（I）：RCO-A（I），其中RCO-是源自多不饱和脂肪酸的酰基，A是源自抗坏血酸的羟基结合的残基。这些产品表现出抗坏血酸向组织或细胞的传递得到改善，使抗坏血酸的功能能够有效展现，并且还具有展示多不饱和脂肪酸功能的潜力。还提供了含有一般化学式（I）表示的6-O-PUFA抗坏血酸酯的食品和饮料。
• Fatty acid derivatives
  申请人：Scotia Holdings PLC

  公开号：US05847000A1

  公开（公告）日：1998-12-08

  Ascorbyl-GLA or Ascorbyl-DGLA in medicaments for treatment of asthma and other disorders.

  抗坏血酸-GLA或抗坏血酸-DGLA在治疗哮喘和其他疾病的药物中使用。
• Skin Care Products, As Well As Foods And Beverages Containing 6-O-Pufa Ascorbic Esters
  申请人：Fukami Harukazu

  公开号：US20080319058A1

  公开（公告）日：2008-12-25

  Skin care products which contain as a vitamin C component 6-O-PUFA ascorbates represented by general formula (I): RCO-A   (I) where RCO— is an acyl group derived from a polyunsaturated fatty acid, and A is a residue of ascorbic acid that binds by —O— derived from the hydroxyl group in ascorbic acid. The products show improved transfer of ascorbic acid to tissues or cells, allow the functions of ascorbic acid to be exhibited efficiently, and also have the potential to show the functions of PUFAs. Also provided are foods and beverages that contain 6-O-PUFA ascorbates represented by general formula (I).

  含有维生素C成分6-O-PUFA抗坏血酸酸酯的护肤品，其通式表示为(I)：RCO-A  (I)，其中RCO—是由多不饱和脂肪酸衍生的酰基，而A是由抗坏血酸中羟基衍生的—O—结合的抗坏血酸残基。该产品显示了抗坏血酸向组织或细胞的转移得到了改善，能够有效地展示抗坏血酸的功能，并具有展示PUFA功能的潜力。还提供了含有通式(I)表示的6-O-PUFA抗坏血酸酸酯的食品和饮料。
• Skin Care Products, As Well As Foods and Beverages Containing 6-O-PUFA Ascorbic Esters
  申请人：FUKAMI Harukazu

  公开号：US20100003208A1

  公开（公告）日：2010-01-07

  Skin care products which contain as a vitamin C component 6-O-PUFA ascorbates represented by general formula (I): RCO-A  (I) where RCO— is an acyl group derived from a polyunsaturated fatty acid, and A is a residue of ascorbic acid that binds by —O— derived from the hydroxyl group in ascorbic acid. The products show improved transfer of ascorbic acid to tissues or cells, allow the functions of ascorbic acid to be exhibited efficiently, and also have the potential to show the functions of PUFAs. Also provided are foods and beverages that contain 6-O-PUFA ascorbates represented by general formula (I).

  含有维生素C成分6-O-PUFA抗坏血酸酸盐的护肤品，其通式表示为(I):RCO-A  (I)，其中RCO—是由多不饱和脂肪酸衍生的酰基，A是由抗坏血酸中羟基衍生的-O-结合的抗坏血酸残基。该产品显示了抗坏血酸酸的有效转移到组织或细胞，使抗坏血酸酸的功能得到有效发挥，并具有展示PUFAs功能的潜力。还提供了含有通式(I)的6-O-PUFA抗坏血酸酸盐的食品和饮料。
• Compositions containing insaturated fatty acids and an aldose reductase inhibitor for treatment of diabetic complications
  申请人：SCOTIA HOLDINGS PLC

  公开号：EP0694302A1

  公开（公告）日：1996-01-31

  Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.

  将 6-不饱和 n-6 脂肪酸，特别是丙三酸（GLA）、二氢丙三酸（DGLA）或花生四烯酸（AA），连同可降低细胞内山梨醇水平的药学上可接受的物质，特别是醛糖还原酶抑制剂，用于治疗（包括预防性治疗）糖尿病的长期并发症，以及制备治疗（包括预防性治疗）糖尿病的药物。上述材料的药物组合物。6- 不饱和 n-6 脂肪酸（GLA 或 DGLA 除外）的抗坏血酸酯本身。